Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo

Journal of Radiation Research

Volumn 46, Issue 3, 2005, Pages 363-372

  Yahiro, T ^a   Masui, S ^a   Kubota, N ^a   Yamada, K ^a   Kobayashi, A ^a   Kishii, K ^a  

^a POLA CHEMICAL INDUSTRIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; MAMMALS; OXYGENATION;

HUMAN PANCREATIC TUMOUR; HUMAN TUMOR CELLS; HYPOXIC CELLS; IN-VITRO; IN-VIVO; RADIATION-INDUCED; RADIO-SENSITIZATION; RADIORESPONSE; RADIOSENSITIZERS; VITRO AND IN VIVO;

TUMORS;

AGOUTI PACA; MURINAE; MUS MUSCULUS;

DORANIDAZOLE; IMIDAZOLE DERIVATIVE; OXYGEN; RADIOSENSITIZING AGENT;

ANIMAL; ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; PANCREAS TUMOR; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMIDAZOLES; MICE; OXYGEN; PANCREATIC NEOPLASMS; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS;

EID: 27744520254     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.46.363     Document Type: Article

References (36)

1. Thomlinson, R. H. and Gray, L, H. (1955) The histrogical structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 9: 539-549.
2. Dische. S. (1985) Chemical sensitizers for hypoxic cells, A decade of experience in clinical. Radiother. Oncol. 3: 97-115.
3. Dische. S. (1991) Hypoxia and local tumor control. Part 2. Radiother. Oncol. 20 (suppl.1): 9-11.
4. th edition, edited by E. J. Hall (Philadelphia, PA: J.B. Lippincott Company). pp. 133-152.
5. Rubin, P., Hanley, J., Keys, H. M., Marcial, V. and Brady, L. (1979) Carbogen breathing during radiation therapy-the Radiation Therapy Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 5: 1963-1970.
6. Bleehen, N. M., Newman, H. F., Maughan, T. S. and Workman, P. (1989) A multiple dose study of the combined radiosensitizers Ro 03-8799 (PIMONIDAZOLE) and SR-2508 (ETANIDAZOLE). Int. J. Radiat. Oncol. Biol. Phys. 16: 1093-1096.
7. Wasserman, T. H., Lee, D. J., Cosmatos, D., Coleman, N., Phillips, T., Davis, L., Marcial, V. and Stetz, J. (1991) Clinical trials with etanidazole (SR-2508) by the radiationtherapy oncology group(RTOG). Radiother. Oncol. Suppl., 20: 129-135.
8. Lee, D. J., Cosmatos, D., Marcial, V. A., Fu, K. K., Rotman, M., Cooper, J. S., Ortiz, H. G., Beitler, J. J., Abrams, R. A., Curran, W. J., Coleman, C. N. and Wasserman, T. H. (1995) Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32: 567-576.
9. Lawton, C. A., Coleman, C. N., Buzydlowski, J. W., Forman, J. D., Marcial, V. A., DelRowe, J. D. and Rotman, M. (1996) Results of a Phase II trial of external beam radiation with etanidazole (SR-2508) for the treatment of local advanced prostate cancer (RTOG PROTCOL 90-20). Int. J. Radiat. Oncol. Biol. Phys. 36:673-680.
10. Rofstad, E. K. and Brustad, T. (1978) The radiosensitizing effect of metronidazole and misonidazole (Ro-07-0582) on a human malignant melanoma grown in the athymic mutant nude mouse. Br. J. Radiol. 51: 381-386.
11. Hill, R. P., Gulyas, S. and Whitmore, G. F. (1986) Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer. 53: 743-751.
12. Sasai, K., Shibamoto, Y., Takahashi, M., Abe, M., Wang, J., Zhou, L., Nishimoto, S. and Kagiya, T. (1989) A newpotent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170. Jpn. J. Cancer. Res. 80: 1113-1118.
13. Shibamoto, Y., Sasai, K., Sakaguchi, M., Tamulevicius, P., Kitakabu, Y., Streffer C. and Abe, M. (1991) Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use. Int. J. Radiat. Biol. 59: 105-115.
14. Taghian, A., Lespinasse, F. and Guichard, M. E. (1991) Radiosensitization by the combination of etanidazole(SR-2508) and pimonidazole(Ro03-8799) in human tumor xenografts. Int. J. Radiat. Oncol. Biol. Phys. 21: 1535-1540.
15. Coleman, C. N., Halsey, J., Cox, R. S., Hirst, V. K., Blaschke, T., Howes, A. E., Wasserman, T. H., Urtasun, R. C., Pajak, T., Hancock, S., Phillips, T. L. and Noll, L. (1987) Relationship between the Neurotoxicity of Hypoxic Cell Radiosensitizer SR 2508 and the Pharmacokinetic Profile. Cancer Res. 47: 319-322.
16. Coleman, C. N., Wasserman, T. H., Urtasun, R. C., Halsey, J., Noll, L., Hancock, S. and Phillips, T. L. (1990) Final report of the Phase I trial of the hypoxic cell radiosensitizer SR 2508 (ETANIDAZOLE) Radiation TherapyOncology Group 83-03. Int. J. Radiat. Oncol. Biol. Phys. 18: 389-393.
17. Brown, J. M. (1995) Hypoxic cell radiosensitizers: The end of an era? Regarding Lee et al., IJROBP 32: 567-576. Int. J. Radiat. Oncol. Biol. Phys. 32: 883-885.
18. Koh, W. J., Bergman, K. S., Rasey, J. S., Peterson, L. M., Evans, M. L., Graham, M. M., Grierson, J. R., Lindsley, K. L., Lewellen, T. K., Krohn, K. A. and Griffin, T. W. (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18] fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33: 391-398.
19. Mariya, Y., Seinberg, F., Streffer, C., Fuhrmann, C. and Abe, Y. (1999) Oxygenation status and tumor response during fractionated irradiation in two murine tumor cell lines of sama origin but different intrinsic radiosensitivities. Radiat. Med. 17: 175-179.
20. Petersen, C., Eicheler, W., Frommel, A., Krause, M., Balschukat, S., Zips, D. and Baumann, M. (2003) Proliferation and micromillieu during fractionated irradiation of human FaDU squamous cell carcinoma in nude mice. Int. J. Radiat. Biol. 79: 469-477.
21. Crane, C. H., Antolak, J. A., Rosen, I. I., Forster, K. M., Evans, D. B., Janjan, N. A., Charnsangavej, C., Pisters, P. W., Lenzi, R., Papagikos, M. A. and Wolff, R. A. (2001) Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int. J. Gastrointest. Cancer. 30: 123-132.
22. Abratt, R. P., Bogart, J. A. and Hunter, A. (2002) Hypofractionated irradiation for non-small cell lung cancer. Lung. Cancer. 36: 225-233.
23. Koukourakis, M. I., Giatromanolaki, A., Kouroussis, C., Kakolyris, S., Sivridis, E., Frangiadaki, C., Retails, G., Georgoulias, V. and Tumor and Angiogenesis Research Group, (2002) Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective post-operative regimen for high-risk breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 52: 144-155.
24. Fowler, J. F., Ritter, M. A., Chappell, R. J. and Brenner, D.J. (2003) What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56: 1093-1104.
25. Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., Bastidas, A. J. and Vierra, M. (2000) Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48: 919-922.
26. Murayama, C., Suzuki, A., SaTO, C, TANABE, Y, Shoji, T., Miyata, Y., Nishio, A., Suzuki, T., Sakaguchi, M. and Mori, T. (1993) Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-trihydroxy- 2′-butoxy)methyl-2-nitroimidazole(RP-343). Int. J. Radiat. Oncol. Biol. Phys. 26: 433-443.
27. Oya, N., Shibamoto, Y., Sasai, K., Shibata, T., Murata, R., Takagi, T., Iwai, H., Suzuki, T. and Abe, M. (1995) Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): Radiosensitization efficiency and toxicity. Int. J. Radiat. Oncol. Biol. Phys. 33: 119-127.
28. Nemoto, K., Shibamoto, Y., Ohmagari, J., Baba, Y., Ebe, K., Ariga, H., Takai, Y., Ouchi, A., Sasai, K., Shinozaki, M., Tsujitani, M., Sakaguchi, M., Yamada, S. and Sakamoto, K. (2001) Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anticancer. Drugs. 12: 1-6.
29. shibamoto, Y., streffer, C., sasai, K., oya, N. and abe, M.(1992) Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int. J. Radiat. Biol. 61: 473-478.
30. 2-histography. Int. J. Radiat. Oncol. Biol. Phys. 19: 953-961.
31. 2 tension measurements. Cancer. Res. 51: 3316-3322.
32. Song, C. W., Shakil, A., Griffin, R. J. and Okajima, K. (1997) Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen breathing. Semin. Oncol. 24: 626-635.
33. Raleigh, J. A., Chou, S. C., Arteel, G. E. and Horsman, M.R. (1999) Comparisons among Pimonidazole Binding, Oxygen Electrode Measurements, and Radiation Response in C3H Mouse Tumors. Radiat. Res. 151: 580-589.
34. OVERGAARD, J. (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6: 509-518.
35. Eschwege F., Sancho-garnier, H., Chassagne, D., Brisgand, D., Guerra, M., Malaise, E. P., Bey, P., Busutti, L., Cionini, L., N'guyen, T., Romanini, A., Chavaudra, J. and Hill, C. (1997) Results of European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 39: 275-281.
36. Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S. C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J. and Raleigh, J. A. (2003) Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother. Oncol. 67: 35-44.